Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer
Launched by ASTRAZENECA · Mar 4, 2008
Trial Information
Current as of July 09, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Advanced ovarian cancer with positive BRCA1 or BRCA2 status
- • Progressive or recurrent disease after platinum-based chemotherapy
- • Measurable disease by RECIST
- Exclusion Criteria:
- • Previous anthracycline treatment
- • Brain metastases
- • Less than 28 days since last treatment used to treat the disease
- • Considered a poor medical risk due to a serious uncontrolled disorder
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Barcelona, , Spain
Houston, Texas, United States
Los Angeles, California, United States
Manchester, , United Kingdom
Leuven, , Belgium
München, , Germany
Haifa, , Israel
London, , United Kingdom
San Francisco, California, United States
Boston, Massachusetts, United States
New York, New York, United States
Sutton, , United Kingdom
Melbourne, Parkville, , Australia
Randwick, , Australia
Köln, , Germany
Hospitalet Dellobregat, , Spain
Cambridge, , United Kingdom
Edinburgh, , United Kingdom
Boca Raton, Florida, United States
East Melbourne, , Australia
Ramat Gan, , Israel
Tel Aviv, , Israel
Szczecin, , Poland
Lund, , Sweden
Patients applied
Trial Officials
Jane Robertson, BSc, MBCHB, MD
Study Director
AstraZeneca
Stan Kaye, BSc, MB, FRCP, FRCR, SMedSCi
Principal Investigator
Royal Marsden NHS Foundation Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials